Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.
You may also be interested in...
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
Genentech Expects Avastin Colon Cancer Data Ahead Of Schedule In 2009
Revised timeline for the C-08 trial does not change Genentech’s assessment of probability of success.